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Abstract
Background: Adenoviral (Ad) vaccine vectors represent both a vehicle to present a novel antigen to the immune system as
well as restimulation of immune responses against the Ad vector itself. To what degree Ad-specific CD8
+ T cells are
restimulated by Ad vector vaccination is unclear, although such knowledge would be important as vector-specific CD8
+ T
cell expansion could potentially further limit Ad vaccine efficacy beyond Ad-specific neutralizing antibody alone.
Methodology/Principal Findings: Here we addressed this issue by measuring human Adenovirus serotype 5 (Ad5)-specific
CD8
+ T cells in recipients of the Merck Ad5 HIV-1 vaccine vector before, during, and after vaccination by multicolor flow
cytometry. Ad5-specific CD8
+ T-cells were detectable in 95% of subjects prior to vaccination, and displayed primarily an
effector-type functional profile and phenotype. Peripheral blood Ad5-specific CD8
+ T-cell numbers expanded after Ad5-HIV
vaccination in all subjects, but differential expansion kinetics were noted in some baseline Ad5-neutralizing antibody (Ad5
nAb) seronegative subjects compared to baseline Ad5 nAb seropositive subjects. However, in neither group did vaccination
alter polyfunctionality, mucosal targeting marker expression, or memory phenotype of Ad5-specific CD8
+ T-cells.
Conclusions: These data indicate that repeat Ad5-vector administration in humans expands Ad5-specific CD8
+ T-cells
without overtly affecting their functional capacity or phenotypic properties. This is a secondary analysis of samples collected
during the 016 trial. Results of the Merck 016 trial safety and immunogenicity have been previously published in the journal
of clinical infectious diseases [1].
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Introduction
Vectors based on the human Adenovirus serotype 5 (Ad5) are
currently leading candidates for vaccines designed to elicit cellular
immunity. Studies both in animals and humans have demonstrat-
ed that Ad5-vectors are capable of inducing potent and sustained
transgene product specific CD4
+ and CD8
+ T-cell responses
[2,3,4]. Additionally, these vectors have been generally safe and
well tolerated [1,5,6]. However, one major hurdle to Ad-vector
based vaccines is the presence of pre-existing Ad-specific
immunity.
Most studies of pre-existing Ad-specific immunity have focused
on neutralizing antibodies (nAb). In animals and humans, Ad5
vaccination is less effective if there are pre-existing Ad5-specific
nAbs [4,7]. Similarly, pre-exposure to Ad5 vector reduces the
efficacy of subsequent booster vaccinations, thereby limiting the
ability for homologous vector boosting [8]. The prevalence of
nAbs to Ad5 varies worldwide, with up to 50% of adults in the
United States and as many as 90% of adults in Africa testing
seropositive [9]. To overcome this limitation, rare Ad serotypes
with low seroprevalence have been developed as vaccine vectors
[10,11,12].
Ad-specific CD4
+ and CD8
+ T-cell responses have also been
detected in humans [13,14]. Previous studies following vaccination
have found Ad5-specific CD8
+ T-cell responses in greater than
80% including baseline seronegative subjects [15,16]. However,
their functional properties, and phenotypic characterization of
Ad5-specific CD8
+ T-cell directly ex vivo before and after
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e14385vaccination are not well described. We have previously done an
extensive characterization of Ad5-specific CD8
+ T-cells following
natural infection, however, it is unclear whether Ad-specific T-cells
stimulated by vaccination are similar to those induced by natural
infection [17]. Moreover, the effect of repeat homologous E1-
deleted Ad5 vector administration upon pre-existing Ad-specific
CD8
+ T cells has not been assessed in human vaccine recipients.
To assess the effect of Ad vector administration on the Ad-
specific CD8
+ T-cell response in humans, we analyzed previously
collected peripheral blood mononuclear cells (PBMCs) from a small
subset of subjects that had been enrolled in a Phase 1 Ad5 vector
human vaccine trial. This study was a basic immunological
investigation designed after the completion of the original trial
and a continuation of work previously performed to characterize
Ad5-specific CD4
+ T-cell responses [18,19]. Using a whole Ad5
vector stimulation together with polyfunctional flow cytometry, we
defined the prevalence, magnitude, functionality and phenotype of
Ad5-specific CD8
+ T-cells before and after Ad5-vector adminis-
tration. Our results demonstrate that while Ad5-specific CD8
+ T-
cells are present in most humans and transiently expand after
vaccination, they do not change in either phenotype or function.
Materials and Methods
Ethics Statement
IRB approval was obtained by Merck at each subject study site:
Emory University, Lehigh University, Western, The Miriam
Hospital Office of Research and AIDS research alliance. Written
informed consent was obtained from all participants. All authors of
this study were blinded to patient identifiers.
Subjects
Frozen peripheral blood mononuclear cells (PBMCs) were
obtained from unvaccinated subjects at week 0 baseline (n=25),
Ad5 seronegative subjects receiving one dose of 3610
10 vp Mrk
Ad5 gag/pol/nef at week 0 and followed through week 4 (n=5),
Ad5 seronegative subjects receiving three doses 3610
10 vp Mrk
Ad5 gag/pol/nef at weeks 0, 4 and 26 (n=5, Ad5 neutralizing
antibody titer #18) and Ad5 seropositive (n=5, Ad5 neutralizing
antibody titer .18) subjects receiving three doses 3610
10 vp Mrk
Ad5 gag/pol/nef at weeks 0, 4 and 26 (n=5) as part of the Merck
phase I 016 trial (Figure S1). The vaccination dose, product, and
schedule was identical to that used in the phase II Merck STEP
HIV-1 vaccine trial. PBMCs were obtained from study weeks 0
(baseline), 4, 8, 18, 26, 30, 42, 52 and 78. Results of the Merck 016
trial safety and immunogenicity have been previously published in
the journal of clinical infectious diseases [1]. The clinical trial
registry number is NCT00849680. This is a secondary analysis of
samples collected during the 016 trial.
Vector and virus
Replication defective Adenovirus 5 (Ad5) and chimpanzee
derived Ad vector of serotype 7 (AdC7) vector as well as wild-type
Ad5 virus were prepared using previously described methods [20].
Vectors and virus were grown on HEK293 cells [21] in DMEM
supplemented with 10% fetal calf serum, antibiotics and
glutamine. Vectors and virus were purified by CsCl gradients
and quality controlled. Quality controls of vectors included testing
for replication-defective adenovirus, which could not be detected
in the E1-deleted Ad5 vector preparations.
Detection of Ad5 hexon transcripts by real-time PCR
CHO-CAR cells were infected at 1000 vp/cell ratio with either
replication-effective Ad5 (Ad5 wt) or replication-defective
Ad5rab.gp or AdC7rab.gp vectors. Non-infected cells were used
as negative control. Forty-eight hours later, total RNA was isolated
using TRI reagent (Sigma, MI), tested by PCR for DNA
contamination, and then reversed transcribed using M-MLV
Reverse Transcriptase (Invitrogen, CA). Samples were adjusted to
equal amounts of gapdH (4.5610
7 copies) as described [22], and
then Ad5 hexon sequence was amplified by PCR (initial cycle of
94uC for 5 min, 35 cycles of 94uC for 60 s, 55uC for 60 s, and
72uC for 60 s, and final cycle of 72uC for 7min) using the following
primers: forward 59 ATCATGCAGCTGGGAGAGTC, and
reversee 59 ACACCTCCCAGTGGAAAGCA. The amplicon
(0.2ml) from the first PCR product was used as template for a
nested quantitative real-time PCR (45 cycles at 95uC for 5 s, 54uC
for 10 s, and 72uC for 15 s; acquisition was at 83uC) conducted
using the LightCycler-RNA amplification kit SYBR Green 1
(Roche, IN). The following primers were used for the nested PCR:
forward 59 GACTCCTAAAGTGGTATTGT, and reverse 59
ACACCTCCCAGTGGAAAGCA. Specificity of amplicons was
confirmed by analyses of melting temperature curves and gel
electrophoresis. Results are shown as the number of mRNA copies
per 10
6 copies of gapdH mRNA.
Antibodies
Directly conjugated antibodies were obtained from the
following: BD Biosciences: TNFa (Pe-Cy7), IFN-c (Alexa700);
Caltag: CD14 (APC-Alexa750), CD19 (APC-Alexa750), Ki67
(Fitc), and CD4 (Pe-Cy5.5); Beckman Coulter: CD8 (ECD), CD27
(Pe-Cy5); and R&D systems: MIP1a (FITC), and IL-2 (APC). We
conjugated the following antibodies in our laboratory: CD3
(QD585), CD57 (QD565), CD45RO (QD705), and Perforin
(Pacific Blue) using standard protocol supplied by the manufac-
turer. We obtained the unconjugated CD45RO and CD57 from
AbD Serotec, perforin BD-49 from Diaclone and CD3 OKT3
from American Type Culture Collection. We obtained Pacific
Blue and Quantum Dots from Invitrogen.
Cell Stimulation and Staining
T cell responses were measured to E1-deleted Ad5 vector that
expressed the rabies virus glycoprotein [23]. 2610
6 PBMCs were
incubated overnight with 1610
11 Ad5 viral particles (vp) and
costimulatory antibodies (aCD28/49d, 1 mg/ml each; BD Biosci-
ences) at 37uC and 5% CO2 in 1 ml complete RPMI media
(RMPI 1640 with 10% heat inactivated FBS, 100 U mL/ml
Penicillin, 100 mg/ml streptomycin sulfate and 1.7 mM sodium
glutamate). A positive control was stimulated with Staphylococcus
enterotoxin B (SEB, 1 mg/ml; Sigma-Aldrich) and a negative
control received only co-stimulatory antibodies. The following
morning we added monensin (Golgi Stop, 0.7 mg/ml; BD
Biosciences) and Brefeldin A (1 mg/ml; Sigma-Aldrich) to each
sample and incubated the cells for six hours at 37uC and 5% CO2.
Samples were then washed in PBS and stained for viability (Aqua
live/dead amine reactive dye; Invitrogen) followed by treatment
with surface antibodies. The cells were permeabilized and fixed
using the Cytofix/Cytoperm kit (BD Biosciences) then stained with
intracellular fluorochome-labeled antibodies. Following staining
cells were washed, fixed (2% paraformaldehyde in PBS) and stored
at 4uC in the dark until analysis.
Flow Cytometry
Cells were analyzed on a modified LSR II flow cytometer (BD
Immunocytometry Systems) with 200,000 to 1,000,000 events
collected per sample. Data was analyzed using FlowJo 8.7.1
(TreeStar). Cells were initially gated to remove doublets, followed
by a lymphocytes gate on forward scatter area versus side scatter
Ad Specific CD8+ T-Cells
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14385area. Dead cells were removed by gating CD3 versus Aqua blue
and removing events that were Aqua blue bright. CD14
+ and
CD19
+ cells were also removed before gating sequentially on
CD3
+, CD8
+/CD4
+ and CD4
2/CD8
2 versus IFN-c. A gate was
then made for each respective function and the Boolean gating
platform used to create the array of 32 possible functional
combinations. Data are reported after background subtraction of
the no stimulation condition. A response greater than 0.05% after
background subtraction was considered positive.
nAb titers
Adenovirus 5 neutralizing antibody titers were measured as
previously described [24]. Briefly, 2610
4 HEK293 cells per well in
a 96 well plate were seeded for 2 days. Ad-SEAP was incubated for
1 hour at 37uC either alone or with serial dilutions of serum then
added to the 95–100% confluent 293 cells and incubated for 1 hr
at 37uC. Supernatant was then removed and replaced with 10%
FBS in DMEM. DEAP expression as measured 2462 hrs later
with the chemiluminescent substrate from the Phospha-Light
TM
kit. (Applied Biosystems).
Statistics
Linear mixed effects models were performed to test for group
differences over time as well as comparisons between baseline and
subsequent time points within each group. Time was considered to
be a discrete variable, lessening the power of these tests compared
to tests where time is a continuous variable. Spearman correlations
were used to test the relationship between Ad5 nAb titers and T-
Figure 1. Baseline CD8
+ T-cell responses. Forty total subjects with a range of Ad5 nAb titers were analyzed. Five seronegative (Ad5 nAb titer
#18, gray symbols) and five seropositive subjects (Ad5 nAb titer .18, black symbols and white boxes) received Merck Ad5 gag/pol/nef as described
in Methods. Each circle represents a subject with lines representing the mean. CD8
+ T-cell responses were measured by flow cytometry following
whole Ad5 vector stimulation. A) Gating strategy for measuring Ad5-specific T cells by intracellular cytokine staining. At least 100,000 PBMCs were
collected on a modified LSR II. Singlets were selected with a FSC-A and FSC-H, followed by a lymphocytes gate, dead cell exclusion, and exclusion of
contaminating CD14
+ monocytes and CD19
+ B-cells. CD3
+ T-cells were selected and then CD8
+ cells by CD8
+CD4
2. Central memory, effector memory
and effector CD8
+ T cells were selected before gating on each cytokine. Because cells can store perforin and these appear perforin
+, Ad5-specific
CD8
+perforin
+ T cells must also be positive for another function to be considered as a responding event. B) Total Ad-specific CD8
+ response. The total
Ad-specific CD8
+ response was computed by summing cells making at least IL-2, IFN-c, MIP1a, or TNFa as measured by flow cytometry. C) There was
no difference in the magnitude of the Ad-specific CD8
+ T-cell response between serogroups at baseline. D) There was no correlation between the
magnitude of Ad-specific CD8
+ T-cell responses and nAb titer at baseline. E) There is a correlation between the magnitude of Ad-specific CD4
+ and
Ad-specific CD8
+ T-cell responses at baseline.
doi:10.1371/journal.pone.0014385.g001
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were computed using partial correlation coefficients controlling for
individual subject effects in the repeated measurements. All data
was transformed using base e. Analyses was performed using SAS
9.1.
Results
To assess the total magnitude, functionality, and phenotypes of
Ad5-specific CD8
+ T-cells, we stimulated human PBMCs with
Ad5 vector and measured CD8
+ T-cell responses by polychro-
matic flow cytometry (Fig. 1A). We detected Ad5-specific CD8
+ T-
cell responses in 95% of all donors at the week 0 baseline (Fig. 1B).
There was no difference in frequencies of Ad5-specific CD8
+ T-
cells between baseline seropositive and seronegative subjects
(Fig. 1C, p.0.05). Likewise there was no correlation between
frequencies of Ad5-specific CD8
+ T-cells and the Ad5 nAb titer at
baseline (Fig. 1D, p.0.05). There was however a positive
correlation between frequencies of baseline Ad5-specific CD4
+
and CD8
+ T-cells (Fig. 1E).
Vector induced CD8
+ T-cell expansion
We next examined the effect of Ad5 vector administration on
the pre-existing Ad5-specific CD8
+ T-cell response. After the
initial vaccine administration, frequencies of Ad5-specific CD8
+ T-
cells in blood increased significantly above pre-vaccination
frequencies in baseline Ad5 seropositive (p,0.0001) but not in
baseline seronegative subjects as a group (Fig. 2A). On an
individual basis, frequencies of Ad5-specific CD8
+ T-cells
increased in three of five seronegative subjects following the initial
dose (data not shown). The remaining two seronegative subjects
without Ad5-specific CD8
+ T-cell expansion had large baseline
responses.
Four weeks after the first homologous Ad5 vector boost at week
4, Ad5-specific CD8
+ T-cell frequencies were higher than baseline
in both subject groups (p,0.03). Following this first boost, Ad5-
specific CD8
+ T-cell responses returned to pre-vaccination levels
in baseline Ad5 seropositive subjects, and were only briefly
expanded again at weeks 30 and 42 following the 2nd boost at
week 26 (p,0.04). In contrast, Ad5-specific CD8
+ T-cell responses
remained elevated above baseline in the seronegative cohort
(p,0.03). The only time we observed a difference in Ad5-specific
CD8
+ T-cell expansion between the seronegative and seropositive
groups was following the third vaccination (weeks 42, 52 and 78;
p,0.03)(Fig. 2A).
The observed increase in Ad5-specific CD8
+ T-cell frequencies
was not reflected by an increase in Ki67 on Ad5-specific CD8
+ T-
cells after either the primary vaccination or subsequent boosts in
either serogroup (Fig. 2B, p=N.S.). Furthermore, we detected
only transient differences in global Ki67 levels on total CD8
+ T-
cells (Fig. 2C). Thus, while increases in Ad5-specific CD8
+ T-cell
Figure 2. Ad-specific CD8
+ T-cells magnitude following vaccination. Five seronegative (Ad5 nAb titer #18, grey circles) and five seropositive
subjects (Ad5 nAb titer .18, white circles) received Merck Ad5 gag/pol/nef as described in Methods. CD8
+ T-cell responses were measured by flow
cytometry following whole Ad5 vector stimulation. Black lines recommend the mean. Grey asterics represent a significant increase from baseline in
seronegative subjects and black asterics represent a significant difference from baseline in seropositive subjects. Black bars represent a significant
difference between the serogroups at that time point. A) Percentage of Ad-specific CD8
+ T-cells. Seronegative subjects were significantly increased
above baseline at week 8 (p,0.03), 26 (p,0.03), 42 (p,0.001), 52 (p,0.01), and 78 (p,0.001). Total Ad-specific CD8
+ T-cells were increased above
baseline in seropositive subjects at week 4 (p,0.0001), 8 (p,0.03), 30 (p,0.02), and 42 (p,0.04). Serogroups significantly differed at week 42
(p,0.02), 52 (p,0.01), and 78 (p,0.003). B) Percentage of Ad-specific Ki67
+ CD8
+ T-cells. C) Percentage of Ki67
+ CD8
+ T-cells. There was a significant
increase above baseline in seronegative subjects at week 4 (p,0.01) and serpositive subjects at week 52 (p,0.12).
doi:10.1371/journal.pone.0014385.g002
Figure 3. AdHu5 hexon quantitative real-time PCR. RNA isolated
from non-infected cells (dashed bar) and from cells infected with
AdC7rab.gp (white bar), Ad5 wt (black bar) or Ad5rab.gp (gray bar) were
reverse transcribed and normalized to equal amount of gapdH mRNA
copies. Ad5 hexon mRNA copies were quantified by real-time PCR using
specific primers. No Ad5 hexon specific mRNA was detected in non-
infected cells or cells infected with AdC7rab.gp. Ad5 hexon mRNA levels
were assessed in triplicates. Averages (Ad5 wt and Ad5rab.gp) and p
values from two-tail student’s t test are shown on top of the bars.
doi:10.1371/journal.pone.0014385.g003
Ad Specific CD8+ T-Cells
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seropositive subjects following vaccination, sustained changes or
global effects on the proliferative capacity of CD8
+ T-cells were
not found.
Transcription of late genes by E1-deleted Ad5 vectors
E1-deleted Ad5 vectors are replication-defective as E1 gene
products are needed to initiate transcription of the other viral
genes. Nevertheless, cellular factors can in part compensate for loss
of E1 and E1-deleted Ad vectors can thus be transcribed and even
proliferate in certain cell types [25,26]. To test if the E1-deleted
Ad5 vector were able to transcribe structural late genes, and thus
be recognized by CD8
+ T cells, CHO cells stably transfected with
a vector expressing the coxsackie adenovirus receptor (CAR) were
infected with 1000 vp per cell of an E1-deleted Ad5 vector,
1000 vp/cell of wild-type Ad5 virus as a positive control or
1000 vp of an E1-deleted chimpanzee-derived Ad vector (AdC7)
as a negative control. RNA was isolated 48 hours later and the
amount of mRNA encoding the viral hexon was determined using
a quantitative real-time PCR with primers designed to distinguish
hexon transcripts of AdHu5 from those of AdC7. Results clearly
showed that hexon was being transcribed although at levels that
were at least 500 fold below those achieved by wild-type virus
(Figure 3). A reduction in vector dose resulted in reduced levels of
transcripts (data not shown). Cells infected with the AdC7 vector
or non-infected cells were negative for Ad5 hexon transcripts.
Vector-induced changes in Ad5-specific CD8
+ T-cell
functionality
At baseline, the majority of Ad5-specific CD8
+ T-cells produced
predominantly the effector functions MIP1a and perforin in both
seropositive and seronegative subjects (Fig. 4A). The percentage of
Ad5-specific CD8
+ T-cells producing TNFa was significantly
higher in baseline seropositive subjects prior to vaccination
(p,0.001) but there were no differences between the groups for
IL-2, IFN-c, MIP1a or perforin.
Having observed increases in the total percentage of Ad5-
specific CD8
+ T-cells following vaccination we next determined
Figure 4. Ad specific T-cell functionality following vaccination. Ten seronegative (Ad5 nAb titer #18, five weeks 0–4, five weeks 0–78, grey
circles) and five seropositive subjects (Ad5 nAb titer .18, white circles) received Merck Ad5 gag/pol/nef as described in Methods. Black lines
recommend the mean. Grey asterics represent a significant increase from baseline in seronegative subjects and black asterics represent a significant
difference from baseline in seropositive subjects. Black bars represent a significant difference between the serogroups at that time point A) Percent
of the total Ad-specific response producing each cytokine. The total Ad-specific CD8
+ response was computed by summing cells making at least IL-2,
IFN-c, MIP1a, or TNFa as measured by flow cytometry. The percentage of the total Ad-specific response was then computed for each cytokine. The
percentage of the total response consisting of TNFa was significantly higher in seropositive subjects (p,0.0005) at baseline. B) Percentage of IL-2
+
Ad-specific CD8
+ T-cells. There was a significant increase above baseline in seronegative subjects at week 42 (p,0.01) and seropositive subjects at
week 4(p=0.015). C) Percentgae of TNFa
+ Ad-specific CD8
+ T-cells. There was a significant increase above baseline in seropositive subjects at week
52 (p,0.01) and 78 (p,0.02) and serpositive subjects at week 4 (p,0.01). There was a significant difference at baseline in the percentage of TNFa
+
CD8
+ T-cells between serogroups (p,0.05). D) Percentage of IFN-c
+ Ad-specific CD8
+ T-cells. The percentage of IFN-c
+ CD8
+T-cells was significantly
increased above baseline in seronegative subjects at weeks 42 (p,0.004), 52 (p,0.003), and 78 (0.009) and in seropositives at weeks (4 (p,0.0001), 8
(p,0.04), 30 (p,0.01) and 42 (p,0.04). There was a significant difference in the percentage of CD8
+IFN-c
+ CD8
+ T-cells at week 78 between the
serogroups (p,0.05). E) Percentage of MIP1a
+ Ad-specific CD8
+ T-cells. Seronegative subjects had a significantly increased percentage of MIP1a
+
CD8
+ T-cells above baseline at weeks 26 (p,0.03), 42 (p,0.001), 52 (p,0.05) and 78 (p,0.004). Seropositive subjects had a significantly increased
percentage of MIP1a
+ CD8
+ T-cells at week 4 (p,0.0005) compared with baseline There was a significant difference in the percentage of MIP1a
+CD8
+
T-cells between the serogroups at weeks 30 (p,0.04), 42 (p,0.012), 52 (p,0.005), and 78 (p,0.001). F) Percentage of perforin
+ Ad-specific CD8
+ T-
cells. The percentage of perforin
+CD8
+ T-cells was significantly increased above baseline at weeks 26 (p,0.02), 42 (p,0.001) 52 (p,0.05) and 78
(p,0.004) in seronegatives and week 4 (p,0.0005) in seropositive subject. There was a significant difference in the percentage of Perforin CD8
+ T-
cells at weeks 42 (p,0.04), 52 (p,0.02) and 78 (p,0.006).
doi:10.1371/journal.pone.0014385.g004
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Consistent with the increase in Ad5-specific CD8
+ T-cell
frequencies following the initial vector vaccination, baseline
seropositive subjects showed a transient increase in percentage of
Ad5-specific CD8
+ T-cells producing IL-2 (Fig. 4B, p=0.015),
TNFa (Fig. 4C, p,0.01), and IFN-c (Fig. 4D, p,0.001) as well as
the MIP1a (Fig. 4E, p,0.0005), and perforin (Fig. 4F, p,0.0002).
The functionality of Ad5-specific CD8
+ T-cells was similar in
baseline seronegative and seropositive subjects, however in
baseline seronegative subjects the expansion of Ad-specific CD8
+
T cells was delayed. Following the third vector dose baseline
seronegative subjects had transiently elevated IL-2 producing
CD8
+ T-cells at week 42(Fig. 4B) and TNFa from weeks 52–
78(Fig. 4C). CD8
+ T cells that produced the effector functions
IFN-c, MIP1a and perforin were expanded for a more prolonged
period of time (weeks 42–78) following the third vector dose. This
delayed expansion resulted in a higher percentage of Ad5-specific
CD8
+ T-cells in baseline seronegative subjects compared with
baseline seropositive subjects following the third vector dose with
MIP1a significantly elevated at weeks 30–78 and perforin at weeks
42–78.
Although we observed increases in the frequencies of Ad5-
specific CD8
+ T-cells producing various functions, the overall
polyfunctionality of Ad5-specific CD8
+ T-cells remained similar to
baseline after vaccination (Fig. 5A, B) in both groups. Further-
more, there was no substantial difference between the groups in
the functional combinations produced (Fig. 5C). In both groups
the major response consisted of cells producing MIP1a with
perforin and MIP1a with IFN-c.
Ad5-specific CD8
+ Phenotype
To investigate whether the effector-like functionality of Ad5-
specific CD8
+ T-cells corresponded to an effector phenotype, we
assessed CD45RO and CD27 expression on Ad5-specific CD8
+ T-
cells. Ad5-specific cells that produced MIP1a, and perforin were
primarily of an effector-like phenotype (CD27-CD45RO-)
(Fig. 6A), whereas more diverse memory subsets produced IFN-
c, TNFa, and IL-2. Approximately half of all Ad5-specific CD8
+
T-cells had an effector like phenotype at baseline in both
seronegative and seropositive subjects (Fig. 6B–C). In baseline
seropositive subjects, vaccination induced transient decreases in
the percentage of Ad5-specific effector CD8
+ T-cells (Fig. 6C,
Figure 5. Polyfunctional Ad-specific CD8
+ T-cell Responses. Five seronegative (Ad5 nAb titer #18, grey circles) and five seropositive subjects
(Ad5 nAb titer .18, white circles) received Merck Ad5 gag/pol/nef as described in Methods. CD8
+ T-cell responses were measured by flow cytometry
following whole Ad5 vector stimulation. A) Percentage of CD8
+ T-cells expressing IFN-c and MIP1a. B) Percentage of Ad-specific CD8
+ T-cells
producing a all five (red) functions: IL-2, MIP1a, TNFa, IFN-c and Perforin, four (blue), three (green), two (orange), or one (yellow) of the five functions
at each time point. Pies represent an average of the two groups. C) Bars represent the percentage of Ad-specific CD8
+ T-cells making a combination
of IL-2, TNFa, MIP1a, Perforin and IFN-c at each week. Positive symbols represent cells staining positive for a function, and minus symbols represent
cells staining negative for a function.
doi:10.1371/journal.pone.0014385.g005
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+ T-cells. Fiveseronegative(Ad5 nAbtiter#18,graycircles)andfiveseropositive subjects(Ad5 nAbtiter
.18, white circles) received Merck Ad5 gag/pol/nef as described in Methods. CD8
+ T-cell responses were measured by flow cytometry following whole
Ad5 vector stimulation. Black lines represent the mean. Grey asterics represent a significant increase from baseline in seronegative subjects and black
asterics represent a significant difference from baseline in seropositivesubjects. Black bars represent a significant difference between the serogroups at
that time point. A) The phenotype of Ad-specific CD8
+ T-cells in a represenative donor. Black areas represent total CD8
+ T-cells and red dots represent
Ad-specific CD8
+ T-cells expressing IL-2, MIP1a, Perforin or TNFa. B) Phenotype of Ad-specific CD8
+ T-cells following vaccination. Black areas represent
total CD8
+ T-cells and red dots represent total Ad-specific CD8
+ T-cells expressing IL-2, MIP1a, Perforin or TNFa. Numbers represent the total percetage
of Ad-specific CD8
+ T-cells. C) Percentage of Ad-specific CD8
+ T-cells with an effector phenotype (CD27-CD45RO2). Seropositive subjects were
significantly decreased from baseline at weeks 4 (p,0.03), 18 (p,0.04), 30 (p,0.01), 42 (p,0.009), 52 (p,0.003). D) Percentage of Ad-specific CD8
+ T-
cells with an effector memory phenotype (CD27-CD45RO
+). Seropositive subjects were significantly increased at weeks 4 (p,0.05), 30 (p,0.02), 52
(p,0.001), 78 (p,0.05). E) Percentage of Ad-specific CD8
+ T-cells with an central memory like phenotype (CD27
+CD45RO
+). Sernegative subjects were
significantly increased above baseline at week 26 (p,0.02) and seropositive subjects were significantly increased from baseline at week 42 (p,0.03).
There was a significant difference between the groups at all time points. (P,0.05). F) Percentage of total CD8
+ T-cells with an effector phenotype
(CD27-CD45RO2). Seropositive subjects were significantly decreased from baseline at weeks 30 (p,0.02), 42 (p,0.002) and 52 (p,0.04). Seronegative
subjects were also significantly decreased from baseline at week 52 (p,0.01). G) Percentage of total CD8
+ T-cells with an effector memory phenotype
(CD27-CD45RO
+). H) Percentage of total CD8
+ T-cells with a central memory like phenotype (CD27
+CD45RO
+). The percentage was significantly
increased in seropositive subjects at weeks 26 (p,0.02), 30 (p,0.002) and 42 (p,0.008) and seronegative subjects at weeks 4 (p,0.04), and 78
(p,0.02). There was a significant difference between the two groups at weeks 26 (p,0.05), 30 (p,0.04), 42 (p,0.03), 52 (p,0.02), and 78 (p,0.01).
doi:10.1371/journal.pone.0014385.g006
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Ad5-specific effector memory cells (CD27-CD45RO
+; Fig. 6D,
p,0.05). In baseline seronegative subjects the effector phenotype
observed at baseline remained stable following vaccination with
only a transient increase in the percentage of Ad5-specific memory
cells observed at week 26 (Fig. 6E). In the total CD8
+ T-cell pool,
the effector phenotype dominated in both serogroups at baseline.
Following vaccination the percentage of all effector CD8
+ T-cell
(Fig. 6F) in seropositive subjects decreased, coinciding with an
increase in all central memory-like CD8
+ T-cells (CD27
+
CD45RO
+; Fig. 6H). In seronegative subjects only transient
changes in total CD8
+ phenotype occurred (Fig. 6F–H). Thus,
while transient changes in memory phenotype were observed after
vaccination, there were no sustained alterations in the memory
phenotype of total or Ad5-specific CD8
+ T-cells in either of the
cohorts. These data suggest that Ad5-based vaccination does not
induce global bystander CD8
+ activation.
Discussion
Recombinant Ad vectors are one of the primary vaccine
platforms that are being tested for a wide range of human
pathogens including HIV, malaria, and tuberculosis [6,27,28].
While these studies primarily focus on the generation of immune
responses against the recombinant insert, an often-overlooked
issue is the induction of vector specific immunity. Here we have
examined Ad5-specific CD8
+ T-cell responses in recipients of an
Ad5 HIV-1 vaccine candidate.
To effectively measure the magnitude of Ad5-specific CD8
+ T-
cell responses against the entire Ad5 vector, we developed a novel
assay for stimulating PBMCs overnight with a recombinant Ad5
vector. We have previously demonstrated that the Ad5 vector
infects antigen presenting cells and is capable of stimulating Ad5-
specific T-cell responses [17]. One limitation of these results is the
possibility that we are detecting CD8
+ T-cell responses against the
rabies glycoprotein insert. This is extremely unlikely as less then
40,000 people, or approximately 0.01% of the US population
receives the rabies vaccine each year and would have pre-existing
immunity to antigens of rabies virus [29]. Antigen presentation of
structural proteins of E1-deleted Ad vectors through the MHC
class I presentation pathway may be achieved through either cross-
presentation or more likely by residual transcription of late Ad
gene products that occurs even with E1-deleted vectors [30]. This
latter notion is further supported by our observation that cells
transfected with E1-deleted vectors produce hexon transcripts
albeit at substantially lower level than cells infected with a
corresponding dose of wild-type virus. Considering that T cells
respond to minute amounts of their cognate antigen we would
assume that such levels that escape detection by conventional
methods designed to detect protein, more than suffice to trigger
stimulation of T cells. One could argue that the Ad vector
transcripts were analyzed in CHO cells rather than in PBMCs or
antigen-presenting cells as previous publications have shown that
complementation of the E1 function is cell type specific [25,26].
We would like to point out that our previous studies have shown
that Ad vectors readily transduce antigen presenting cells [31] and
furthermore that Ad vectors persist in a transcriptionally active
form in lymphocytes, especially activated T cells, suggesting that
such cells most likely provide factors that allow for the expression
of structural proteins of Ad vectors [32].
We find that regardless of baseline Ad5 nAb serostatus, Ad5
vector administration results in a potent restimulation and
expansion of pre-existing Ad5-specific CD8
+ T-cells. This finding
by itself is curious. One would have expected that E1-deleted Ad
vectors only produce trace amounts of structural Ad proteins, as
the transcription of late genes is under the control of a gene
product of the deleted E1 domain. Nevertheless, as has been
shown by others, CD8
+ T cell responses to Ad vector particle
proteins can be induced efficiently by cross-priming. This
mechanism would circumvent the need for de novo synthesis of
Ad structural proteins for induction or recall of Ad-specific CD8
+
T cells [33].
At baseline, Ad5-specific CD8
+ T-cells were detectable in 38 of
40 subjects, despite a seroprevalence in the US of up to only 50%.
This magnitude of Ad5 -reactive CD8
+ T-cells is consistent with
smaller studies showing Ad5-specific CD8
+ T-cell responses in
greater than 80% of subjects [14,15,16]. The prevalence of Ad5-
specific CD8
+ T-cells is likely the result of cross-reactive CD8
+ T-
cell generated from infection with alternate serotypes. Many Ad
proteins have highly conserved regions between various Ad
serotypes, likely resulting in conservation of T cell epitopes and
the generation of cross-serotype reactive Ad5-specific CD8
+ T-
cells. Although we were able to observe a high frequency of
responders after stimulation with an Ad5 vector in vitro, it is unclear
whether detected responses were induced by a natural infection
with an Ad5 virus.
Although vaccination increased frequencies of Ad5-specific
effector CD8
+ T-cells in both serogroups, there were no significant
changes either within or between the groups for the cell cycle
marker Ki67. Though the PBMC sampling in this study was
intensive, there was a four-week period between vaccination and
PBMC collection. It is possible that expansion of Ad5-specific T-
cells and expression of Ki67 occurred transiently during this
period. Alternatively, Ki67
+ Ad5-specific CD8
+ T-cells may have
trafficked out of the peripheral blood by this time.
Interestingly, we observed no changes in polyfunctionality of
Ad5-specific CD8
+ T-cells compared to baseline following
vaccination in either serogroup. As we have previously observed
[17], Ad5-specific CD8
+ T-cells are continuously maintained in
both a functionally and phenotypically effector-like state in most
individuals, likely reflecting continued or intermittent exposure to
Ad viruses. Ad5 vector administration did not alter this functional
response, and instead further expanded it. This expansion could
potentially reduce the effectiveness of Ad vaccine boosting with
both homologous and heterologous Ad vectors by the direct
elimination of vector-transduced cells.
Supporting Information
Figure S1 Study Design. Frozen PBMCs from 40 subjects who
had previously participated in a Merck Ad5 gag/pol/ned phase I
trial (016) were utilized for this smaller basic immunology study.
The study consisted of 25 unvaccinated subjects used for baseline
comparison, five baseline seronegative subjects who received one
dose 361010 vp Merck Ad4 gag/pol/nef at week 0 and were
analyzed at weeks 0 and 4, five baseline seronegative subjects who
received three dose 361010 vp Merck Ad4 gag/pol/nef at week 0,
4 and 26 and five baseline seropositive subjects who received three
dose 361010 vp Merck Ad4 gag/pol/nef at week 0, 4 and 26. For
subjects receiving three doses, PBMCs were analyzed from weeks
0, 4, 8, 18, 26, 30, 42, 52 and 78.
Found at: doi:10.1371/journal.pone.0014385.s001 (0.06 MB
TIF)
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